ENHERTU is a specialized treatment brand focused on delivering innovative therapeutic options for patients with HER2-positive and HER2-low breast cancer, HER2-mutant non-small cell lung cancer (NSCLC), and other solid tumors. This conjugate therapy, combining an antibody with a chemotherapy agent, is designed for patients who have previously received anti-HER2 treatments.

ENHERTU4U, the support program for ENHERTU, provides essential resources for healthcare professionals and patients alike, facilitating access to treatment through benefit verification, prior authorization assistance, and financial support options. With a dedicated team of Field Reimbursement Managers and nursing support, ENHERTU4U ensures comprehensive assistance, addressing coding and reimbursement queries to aid healthcare providers in navigating the treatment process.

Patients prescribed ENHERTU are encouraged to access these support options while being informed of potential risks, including interstitial lung disease and the need for close monitoring. For more information about the product and support services, patients and providers can contact 1-833-ENHERTU.